Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers

BACKGROUND: Tumor mutational burden (TMB) has been widely studied as a predictive biomarker of response to immune checkpoint inhibitors (ICIs). Besides, evidence suggests frameshift indels are a highly immunogenic mutational class and thus a potentially superior biomarker. However, the general progn...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Transl Med
Main Authors: Wu, Hao-Xiang, Wang, Zi-Xian, Zhao, Qi, Chen, Dong-Liang, He, Ming-Ming, Yang, Lu-Ping, Wang, Ying-Nan, Jin, Ying, Ren, Chao, Luo, Hui-Yan, Wang, Zhi-Qiang, Wang, Feng
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6944566/
https://ncbi.nlm.nih.gov/pubmed/31930041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.10.116
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados